drugset / Trial / NCT04427449

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

NCT04427449 ↗

Phase 1/2 Recruiting 100 enrolled Shenzhen Geno-Immune Medical Institute
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.

Timeline

Start
2026-06-01
Primary completion
2029-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 4SCAR-CD44v6 T cells Cell therapy 1e+06 cells/kg Intravenous

Indications

No indication recorded.